High ROIC Stocks
ZTS is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
ZOETIS INC (ZTS) Stock Price & Overview
NYSE:ZTS • US98978V1035
Current stock price
117.94 USD
+0.65 (+0.55%)
At close:
117.94 USD
0 (0%)
After Hours:
The current stock price of ZTS is 117.94 USD. Today ZTS is up by 0.55%. In the past month the price decreased by -3.51%. In the past year, price decreased by -22.27%.
ZTS Key Statistics
52-Week Range113.29 - 172.23
Current ZTS stock price positioned within its 52-week range.
1-Month Range113.29 - 122.965
Current ZTS stock price positioned within its 1-month range.
- Market Cap
- 49.786B
- P/E
- 18.37
- Fwd P/E
- 16.66
- EPS (TTM)
- 6.42
- Dividend Yield
- 1.64%
ZTS Stock Performance
Today
+0.55%
1 Week
+1.12%
1 Month
-3.51%
3 Months
-6.34%
Longer-term
6 Months -19.45%
1 Year -22.27%
2 Years -25.94%
3 Years -32.90%
5 Years -31.84%
10 Years +150.78%
ZTS Stock Chart
ZTS Stock Screens
ZTS currently appears in the following ChartMill screener lists.
Dividend Growth Stocks
ZTS is part of our Dividend Growth Stocks screen, indicating it has a reliable dividend with grows strongly
ZTS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ZTS. When comparing the yearly performance of all stocks, ZTS is a bad performer in the overall market: 82.67% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ZTS Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to ZTS. While ZTS belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ZTS Earnings
On February 12, 2026 ZTS reported an EPS of 1.48 and a revenue of 2.39B. The company beat EPS expectations (4.53% surprise) and beat revenue expectations (0.13% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$1.48
Revenue Reported2.387B
EPS Surprise 4.53%
Revenue Surprise 0.13%
ZTS Forecast & Estimates
25 analysts have analysed ZTS and the average price target is 150.27 USD. This implies a price increase of 27.41% is expected in the next year compared to the current price of 117.94.
For the next year, analysts expect an EPS growth of 10.25% and a revenue growth 4.91% for ZTS
Analysts
Analysts76.8
Price Target150.27 (27.41%)
EPS Next Y10.25%
Revenue Next Year4.91%
ZTS Groups
Sector & Classification
Sector
Health Care Sub-Industry
Pharmaceuticals ZTS Financial Highlights
Over the last trailing twelve months ZTS reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 8.45% compared to the year before.
Income Statements
Revenue(TTM)9.47B
Net Income(TTM)2.67B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.23% | ||
| ROA | 17.28% | ||
| ROE | 80.25% | ||
| Debt/Equity | 2.71 |
Chartmill High Growth Momentum
EPS Q2Q%5.71%
Sales Q2Q%3.02%
EPS 1Y (TTM)8.45%
Revenue 1Y (TTM)2.28%
ZTS Ownership
Ownership
Inst Owners100.79%
Shares422.13M
Float421.44M
Ins Owners0.07%
Short Float %3.73%
Short Ratio3.45
ZTS Latest News, Press Relases and Analysis
12 days ago - By: Chartmill
ZTS Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZTS
Company Profile
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Company Info
IPO: 2013-02-01
ZOETIS INC
10 Sylvan Way
Parsippany NEW JERSEY 07054 US
CEO: Kristin C. Peck
Employees: 14500
Phone: 13026587581
ZOETIS INC / ZTS FAQ
What does ZOETIS INC do?
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Can you provide the latest stock price for ZOETIS INC?
The current stock price of ZTS is 117.94 USD. The price increased by 0.55% in the last trading session.
What is the dividend status of ZOETIS INC?
ZOETIS INC (ZTS) has a dividend yield of 1.64%. The yearly dividend amount is currently 2.04.
What is the ChartMill rating of ZOETIS INC stock?
ZTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for ZTS stock?
25 analysts have analysed ZTS and the average price target is 150.27 USD. This implies a price increase of 27.41% is expected in the next year compared to the current price of 117.94.
How is the valuation of ZOETIS INC (ZTS) based on its PE ratio?
The PE ratio for ZOETIS INC (ZTS) is 18.37. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 117.94 USD.
Would investing in ZOETIS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZTS.